![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
Z Jayyosi, D Knoble, M Muc, J Erick, PE Thomas and M Kelley
Rhone-Poulenc Rorer Central Research, Drug Safety Division, Collegeville, Pennsylvania, USA.
The contribution of individual cytochrome P-450 isozymes in the hydroxylation of the centrally acting skeletal muscle relaxant chlorzoxazone was determined in rat liver microsomes. The hydroxylation rate of chlorzoxazone was found to be 50% greater in male than female microsomes. Kinetic studies using control male microsomes showed that chlorzoxazone hydroxylation was biphasic with a calculated low Km (33 microM) and high Km (116 microM). Liver microsomes from isoniazid-, beta-naphthoflavone- or dexamethasone-treated male rats produced a Km of 93, 69 and 26 microM, respectively. When chlorzoxazone hydroxylation activity was measured at a high substrate concentration (200 microM), treatment of male rats with isoniazid, acetone, beta-naphthoflavone and dexamethasone produced increases in the activity rate of 124%, 117%, 81% and 32%, respectively. However, when the activity was measured at a low substrate concentration (2 microM), liver microsomes from dexamethasone-treated male and female rats produced 5- and 10-fold induction, respectively. In immunoinhibition studies at 200 microM of chlorzoxazone, antibodies specific for cytochrome P-450 2E1 inhibited the rate of chlorzoxazone hydroxylation in microsomes from control and isoniazid-treated male rats by 68% and 79%, respectively. A monoclonal antibody (C8) against P-450 1A1 inhibited 67% of the activity in microsomes from beta-naphthoflavone-treated male rats but was ineffective inhibiting chlorzoxazone hydroxylation in microsomes from control or dexamethasone-treated male rats. In liver from control female rats, antibodies against cytochrome P-450 2E1 inhibited 80% of chlorzoxazone hydroxylation, whereas it inhibited only 47% of the activity in dexamethasone-treated females.(ABSTRACT TRUNCATED AT 250 WORDS)
This article has been cited by other articles:
|
|
 |
|
  C. Y. Ahn, S. K. Bae, Y. S. Jung, I. Lee, Y. C. Kim, M. G. Lee, and W. G. Shin Pharmacokinetic Parameters of Chlorzoxazone and Its Main Metabolite, 6-Hydroxychlorzoxazone, after Intravenous and Oral Administration of Chlorzoxazone to Liver Cirrhotic Rats with Diabetes Mellitus Drug Metab. Dispos., July 1, 2008; 36(7): 1233 - 1241. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Vuppugalla and R. Mehvar SELECTIVE EFFECTS OF NITRIC OXIDE ON THE DISPOSITION OF CHLORZOXAZONE AND DEXTROMETHORPHAN IN ISOLATED PERFUSED RAT LIVERS Drug Metab. Dispos., July 1, 2006; 34(7): 1160 - 1166. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Vuppugalla and R. Mehvar ENZYME-SELECTIVE EFFECTS OF NITRIC OXIDE ON AFFINITY AND MAXIMUM VELOCITY OF VARIOUS RAT CYTOCHROMES P450 Drug Metab. Dispos., June 1, 2005; 33(6): 829 - 836. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Vuppugalla and R. Mehvar Hepatic Disposition and Effects of Nitric Oxide Donors: Rapid and Concentration-Dependent Reduction in the Cytochrome P450-Mediated Drug Metabolism in Isolated Perfused Rat Livers J. Pharmacol. Exp. Ther., August 1, 2004; 310(2): 718 - 727. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Poloyac, M. A. Tortorici, D. I. Przychodzin, R. B. Reynolds, W. Xie, R. F. Frye, and M. A. Zemaitis THE EFFECT OF ISONIAZID ON CYP2E1- AND CYP4A-MEDIATED HYDROXYLATION OF ARACHIDONIC ACID IN THE RAT LIVER AND KIDNEY Drug Metab. Dispos., July 1, 2004; 32(7): 727 - 733. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. A. Howard, A. L. Micu, E. M. Sellers, and R. F. Tyndale Low Doses of Nicotine and Ethanol Induce CYP2E1 and Chlorzoxazone Metabolism in Rat Liver J. Pharmacol. Exp. Ther., November 1, 2001; 299(2): 542 - 550. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. H. Lash and J. C. Parker Hepatic and Renal Toxicities Associated with Perchloroethylene Pharmacol. Rev., May 11, 2001; (2001) 2. [Abstract] [Full Text]
|
|
|
|
|
|
K. Rockich and R. Blouin Effect of the Acute-Phase Response on the Pharmacokinetics of Chlorzoxazone and Cytochrome P-450 2E1 In Vitro Activity in Rats Drug Metab. Dispos., September 1, 1999; 27(9): 1074 - 1077. [Abstract] [Full Text]
|
|
|
|
|
|
B. S. Cummings, R. C. Zangar, R. F. Novak, and L. H. Lash Cellular Distribution of Cytochromes P-450 in the Rat Kidney Drug Metab. Dispos., April 1, 1999; 27(4): 542 - 548. [Abstract] [Full Text]
|
|
|
|
|
|
G. W. Warren, S. M. Poloyac, D. S. Gary, M. P. Mattson, and R. A. Blouin Hepatic Cytochrome P-450 Expression in Tumor Necrosis Factor-alpha Receptor (p55/p75) Knockout Mice After Endotoxin Administration J. Pharmacol. Exp. Ther., March 1, 1999; 288(3): 945 - 950. [Abstract] [Full Text]
|
|
|
|
|
|
G. Amato, V. Longo, A. Mazzaccaro, and P. G. Gervasi Chlorzoxazone 6-Hydroxylase and p-Nitrophenol Hydroxylase as the Most Suitable Activities for Assaying Cytochrome P450 2E1 in Cynomolgus Monkey Liver Drug Metab. Dispos., May 1, 1998; 26(5): 483 - 489. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. W. Linder, R. A. Prough, and R. Valdes Jr. Pharmacogenetics: a laboratory tool for optimizing therapeutic efficiency Clin. Chem., February 1, 1997; 43(2): 254 - 266. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. K. Grant, B. G. Green, R. Wang, S. G. Pacholok, and J. W. Kozarich Characterization of Inducible Nitric-oxide Synthase by Cytochrome P-450 Substrates and Inhibitors. INHIBITION BY CHLORZOXAZONE J. Biol. Chem., January 10, 1997; 272(2): 977 - 983. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. H. Lash and J. C. Parker Hepatic and Renal Toxicities Associated with Perchloroethylene Pharmacol. Rev., June 1, 2001; 53(2): 177 - 208. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
